B+
Bull case
25%
Probability
Target price
$280.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
ALNY
AlnylamCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$230.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$165.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-06
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+54.3
Score
AI commentary
The supplied recent-news items are mostly unrelated to Alnylam, so they do not establish positive company-specific news tone. The October 5 price anchor is not a verified post-release reaction measure. Social, options, short-interest, employee, and post-guidance analyst-revision data are unavailable; zero values in the sentiment fields denote unavailable measurements, not neutral observations. The structured prior is positive but has lower catalyst density than the earlier baseline, supporting cautious monitoring rather than an upgrade.
RankAlpha Sentiment Codex - 2026-10-06
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-23eventALN-HTT02 Phase 1 data at EHDNHigh impact
Alnylam said initial Huntington's disease Phase 1 results would be presented at EHDN. The congress runs October 22–24, 2026; October 23 is a monitoring date, not a confirmed presentation slot. Safety and efficacy remain unestablished. [#8-K-2026-07-30] [#SEC-8K-2026-07-30] EHDN congress schedule
2026-11-15catalystATTR-CM launch-volume test after guidance cutHigh impact
Q2 2026 global product revenue was $1.172 billion, but Alnylam cut full-year TTR revenue guidance from $4.4–$4.7 billion to $4.2–$4.5 billion. Management attributed the reset partly to normalization of second-line volume after pent-up demand. Subsequent sales will test whether diagnosis and treatment growth offsets that normalization; the date is an estimated review window, not an announced reporting date. [#8-K-2026-07-30] [#SEC-8K-2026-07-30]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-06 • Updated nightlySource: Internal modelMethodology